Omega-3 Emulsion Compositions for Enhanced Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current omega-3 fatty acid formulations, such as LOVAZA®, do not adequately reduce triglyceride levels in all patients, and there is a need to enhance the therapeutic effect while minimizing the administration burden, including pill size and frequency, to improve patient compliance and reduce side effects.
Innovation Solution
Development of novel emulsion compositions and emulsion pre-concentrate compositions with a median particle size of 100 nm to 3 μm, comprising an aqueous phase, an omega-3 fatty acid oil, and a surfactant, which increase oral absorption and bioavailability of omega-3 fatty acids, allowing for reduced dosage and frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional omega-3 fatty acid formulations (e.g., LOVAZA®) are used, then triglyceride levels can be reduced to some extent, but the therapeutic effect is insufficient in all patients and the administration burden remains high
Solution Approach 1:
The patent changes the physical and chemical parameters of omega-3 fatty acid delivery by formulating them as emulsions with specific particle sizes (100-300 nm) and adjusting composition ratios (omega-3 fatty acid content, surfactant concentration, water content) to enhance absorption and reduce administration burden
Solution Approach 2:
The patent introduces surfactants as intermediary substances that facilitate the formation and stabilization of emulsion droplets, enabling better absorption of omega-3 fatty acids while allowing for reduced dosage and frequency of administration
2Reliability
If the dosage amount and frequency of omega-3 fatty acid administration are increased, then the therapeutic effect is enhanced, but the administration burden and side effects increase
Solution Approach 1:
The patent optimizes parameters including emulsion particle size (100-300 nm), omega-3 fatty acid concentration (15-30 wt%), and surfactant content (5-10 wt%) to maximize therapeutic efficacy at lower dosages, thereby reducing side effects while maintaining effective treatment
3Quantity of substance
If emulsion formulations with smaller particle sizes are used, then oral absorption and bioavailability of omega-3 fatty acids are enhanced, but the formulation complexity increases
Solution Approach 1:
The patent specifies precise parameter ranges for emulsion formulation including particle size (100-300 nm), omega-3 fatty acid content (15-30 wt%), surfactant concentration (5-10 wt%), and water content (65-80 wt%) to achieve enhanced absorption while maintaining manageable formulation complexity through defined synthesis procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The emulsion compositions enhance the exposure and absorption of omega-3 fatty acids, effectively reducing triglyceride levels and enabling lower dosage requirements, thus improving therapeutic outcomes with reduced administration burden.
Implementation Method 1
an emulsion composition comprising: an aqueous phase comprising an aqueous liquid; an oil phase comprising an omega-3 fatty acid oil; and a surfactant
Implementation Method 2
the emulsion compositions enhance the exposure and absorption of omega-3 fatty acids, effectively reducing triglyceride levels
Data Source
AI summary
Novel compositions comprising omega-3 fatty acids and uses thereof are disclosed.